Byongen Therapeutics

Explore the latest insights on Byongen Therapeutics and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Byongen Therapeutics’ developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Explore the latest insights on Byongen Therapeutics and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Byongen Therapeutics' developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Bio‑Thera’s BAT2306 Becomes World’s First Secukinumab Biosimilar with NMPA Approval Across Psoriasis, Ankylosing Spondylitis and Psoriatic Arthritis

Bio‑Thera Solutions, Ltd. (SHA: 688177) announced that China's National Medical Products Administration (NMPA) has approved the Marketing Authorization Application for its Secukinumab Injection (BAT2306), indicated for the treatment of psoriasis,…

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.